 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: OCREVUS (ocrelizumab) |
|
***************************************************** |
|
#Post#: 2891-------------------------------------------------- |
|
1st PML case with ocrelizumab alone reported |
|
By: agate Date: April 30, 2020, 6:57 pm |
|
--------------------------------------------------------- |
|
The first clear-cut case of PML in an MS patient taking Ocrevus |
|
has been reported--and the patient (age 78) died. Sad news |
|
indeed. From Medscape Neurology (April 30, 2020), "Report |
|
Details First Case of PML with Ocrelizumab Alone": |
|
https://www.medscape.com/viewarticle/929728 |
|
#Post#: 2892-------------------------------------------------- |
|
Re: 1st PML case with ocrelizumab alone reported |
|
By: agate Date: April 30, 2020, 7:08 pm |
|
--------------------------------------------------------- |
|
Here is the abstract of the report mentioned in the article |
|
cited in the previous post. |
|
AAN abstract (2020--exact date not given), "Progressive |
|
multifocal leukoencephalopathy in a patient on ocrelizumab |
|
monotherapy": |
|
https://index.mirasmart.com/AAN2020/PDFfiles/AAN2020-004875.html |
|
The last sentence of the Conclusions section might be worth |
|
noting: |
|
[quote]This case emphasizes the importance of a thorough |
|
discussion of the risks and benefits of ocrelizumab, especially |
|
in patients at higher risk for infections, such as the |
|
elderly.[/quote] |
|
#Post#: 2896-------------------------------------------------- |
|
(Abst.) Risk factors in developing lymphopenia and hypogammaglob |
|
ulinemia... |
|
By: agate Date: May 6, 2020, 12:46 am |
|
--------------------------------------------------------- |
|
A paper prompted by this case (apparently) was presented to the |
|
AAN (American Academy of Neurology), which has scheduled virtual |
|
presentations of research papers in May and June instead of its |
|
usual annual meeting, which was canceled on account of COVID-19. |
|
This is the abstract of the paper, "Evaluation of risk factors |
|
in developing lymphopenia and hypogammaglobulinemia in anti-CD20 |
|
treated multiple sclerosis patients": |
|
https://index.mirasmart.com/AAN2020/PDFfiles/AAN2020-005218.html |
|
***************************************************** |
